10x Genomics (TXG) Accumulated Depreciation & Amortization (2018 - 2026)

10x Genomics' Accumulated Depreciation & Amortization history runs 9 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation & Amortization rose 24.12% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (up 24.12% YoY), while the FY2025 annual figure was $36.2 million, up 0.89% from the prior year.
• Accumulated Depreciation & Amortization came in at $10.0 million for Q1 2026 at 10x Genomics, down from $36.2 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $36.2 million in Q4 2025 to a low of $6.5 million in Q1 2023.
• A 5-year average of $20.5 million and a median of $18.5 million in 2022 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization jumped 41.84% in 2024 and retreated 12.82% in 2025, its largest moves.
• 10x Genomics' Accumulated Depreciation & Amortization stood at $25.4 million in 2022, then surged by 39.99% to $35.5 million in 2023, then advanced by 1.03% to $35.9 million in 2024, then grew by 0.89% to $36.2 million in 2025, then tumbled by 72.49% to $10.0 million in 2026.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $10.0 million, $36.2 million, and $26.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison